Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7762 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD7762 monotherapy followed by AZD7762 + gemcitabine |
| Name | Type | Description |
|---|---|---|
| AZD7762 | DRUG | intravenous infusion |
| Gemcitabine | DRUG | weekly intravenous infusion |
Inclusion Criteria: * Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * ECOG performance status of 0 or 1 * Patient and tumor type must be suitable for treatment wi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AZD7762 is an investigational small molecule developed for the treatment of advanced solid tumors. It was studied in patients with advanced solid malignancies, including administration alone and in combination with gemcitabine. It is not an approved therapy and remains in clinical development.
AZD7762 targets CHEK1, also known as checkpoint kinase 1. It acts as an inhibitor of this target. CHEK1 is involved in cell cycle checkpoint control, and inhibiting it is the intended mechanism of action for this small molecule in oncology research.
AZD7762 is developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the clinical study of the compound in patients with advanced solid malignancies.
AZD7762 is in Phase 1 development. It is investigational and has not been approved for any indication. The single Phase 1 trial evaluating the compound has been completed.
AZD7762 was evaluated in one Phase 1 trial, NCT00413686, titled a study to assess safety of AZD7762 administered alone and in combination with gemcitabine in patients with advanced solid malignancies. The trial enrolled 42 patients in the United States and is completed.